Subscribe to our Newsletters !!
In molecular biology, the LAMP (Loop-Mediated Isot
Pharmaceutical laboratories have been adopting imm
Generally, a debate about Isopure protein and regu
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
In a world constantly in motion, Microbioz India r
Drug major Glenmark Pharma on Wednesday said it has received final approval from the US health regulator for Dimethyl Fumarate delayed-release capsules, used for treatment of relapsing forms of multiple sclerosis in adults. Quoting IQVIA sales data for the 12 month period ending August 2020, Glenmark said Tecfidera delayed-release capsules, 120 mg and 240 mg, market achieved annual sales of approximately USD 3.8 billion.
Glenmark said current portfolio consists of 164 products authorised for distribution in the US marketplace and 46 abbreviated new drug applications are pending approval with the USFDA.